Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

933
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
933
Standard Precaution01:26

Standard Precaution

2.1K
Standard precautions are the minimum infection control safeguards used while caring for all patients, irrespective of their disease condition. They help prevent the spread of common infectious microorganisms to healthcare workers, patients, and visitors in all healthcare settings.
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
2.1K
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.3K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.3K
Subviral Agents01:29

Subviral Agents

59
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
59
PPE Use in Healthcare Settings II: Doffing01:10

PPE Use in Healthcare Settings II: Doffing

1.0K
The sequence of removing or doffing PPE starts with the gloves, as they are the most contaminated. Next is removal of the face shield or goggles, as they would interfere with removing other PPE. Then remove the gown, followed by the mask or respirator. Perform hand hygiene between steps if hands become contaminated and immediately after removing all PPE. Generally, the outside front and sleeves of the isolation gown, the goggles or the mask, the respirator, and the face shield are contaminated.
1.0K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

185
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
185

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct Oral Challenge for Penicillin Allergy: The International Network of Antibiotic Allergy Nations (iNAAN) Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Direct Oral Challenge for Penicillin Allergy: A Hospital Implementation Evaluation Via the International Network of Antibiotic Allergy Nations (iNAAN) Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Clinical risk factors and antimicrobial resistance associated with campylobacteriosis in Melbourne, Australia: a retrospective analysis.

Internal medicine journal·2026
Same author

Anti-NMDA receptor encephalitis following Murray Valley encephalitis: a case report.

ASM case reports·2025
Same author

An Atypical Presentation of Culture-Negative Cryptococcal Meningitis in an Immunocompetent Host With Prior Stroke: A Case Report.

Case reports in infectious diseases·2025
Same author

Predictive factors for lower extremity amputations in patients with diabetic foot disease in Central Australia.

Internal medicine journal·2025

Related Experiment Video

Updated: Aug 6, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.6K

Healthcare worker access to molnupiravir: A case series.

Jessica C O'Keeffe1,2, Meg Constable3, Janice Chiang4

  • 1Department of Infectious Diseases, Barwon Health, Geelong, Victoria, Australia.

Plos One
|March 14, 2023
PubMed
Summary

Molnupiravir access for Australian healthcare workers, even without PBS eligibility, reduced illness duration and household transmission of COVID-19. This supports broader access to improve staff wellbeing and healthcare system resilience.

More Related Videos

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

15.8K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

15.7K

Related Experiment Videos

Last Updated: Aug 6, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.6K
Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

15.8K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

15.7K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Public Health

Background:

  • Molnupiravir is an oral antiviral effective in reducing COVID-19 severity.
  • Australian Pharmaceutical Benefits Scheme (PBS) access to molnupiravir is restricted for those under 70 without specific risk factors, excluding most healthcare workers.
  • Australian healthcare services face significant strain due to COVID-19-related staff shortages.

Purpose of the Study:

  • To evaluate the effectiveness and safety of molnupiravir in Australian healthcare workers ineligible for PBS.
  • To assess the impact of early molnupiravir treatment on illness duration, return to work, and household transmission.
  • To explore the potential benefits of expanded molnupiravir access for healthcare workforce wellbeing and system capacity.

Main Methods:

  • A study involving thirty tertiary hospital staff members who received molnupiravir within five days of COVID-19 diagnosis.
  • Data collection on adverse events, duration of illness, return-to-work status, and household transmission.
  • Analysis of outcomes in a cohort not meeting standard PBS eligibility criteria.

Main Results:

  • All participants completed molnupiravir treatment with low rates of adverse events, comparable to clinical trial data.
  • Median illness duration was four days, with 81% testing negative by rapid antigen test on the final treatment day.
  • 73% were well enough to return to work post-isolation, and only 22% reported household transmission after starting treatment.

Conclusions:

  • Early molnupiravir treatment offers individual health benefits for healthcare workers, including faster recovery and reduced transmission.
  • Expanding access to molnupiravir for healthcare workers could mitigate staff shortages and enhance healthcare system resilience.
  • Policy adjustments regarding molnupiravir access may support the wellbeing of essential healthcare personnel during the pandemic.